1School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road, Phagwara, Punjab (India)-144411
2Department of Rasa Shastra and Bhaishjya Kalpana (Ayurvedic Pharmaceutics), Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Uttar Pradesh, India.
3Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Punjab, India
*Corresponding Author E-mail: dileep.15210@lpu.co.in
Online published on 30 April, 2021.
Background: Punarnava (B. diffusa Linn.) is usually prescribed in India as traditional medicine in the management of renal miseries including CaOx (calcium oxalate) urolithiasis (Mutrakrichra). It occurs commonly as a weed throughout India. Out of the forty species of this genus B. diffusa, B. chinensis, B. erecta, B. rependa, and B. rubicunda have Indian originates. Objective: To prepare Punarnava ghan tablet and evaluate its potential against Urolithiasis (Mutrakrichra) by in vitro technique. Materials and Methods: Punarnava kwath churna were prepared as per the methodology mentioned in Sharandhar samhita and ghan was prepared by evaporating the watery portion from prepared kwath. Prepared ghan was compressed into tablet, and for evaluating the quality of tablets standard parameters were determined. Results: Physicochemical and stability studies have not shown any remarkable variations with prepared tablet dosage form. In vitro studies showed 50% of crystal inhibition at 650μg/ml. Conclusion: The prepared tablets of Punarnava ghan did not have remarkable variation during physicochemical and stability studies. The prepared tablets were able to so remarkable in vitro activity against Urolithiasis (Mutrakrichra).
Mutrakrichra, Boerhaavia diffusa, Punarnava, Ghan, Tablet, Stability studies, Antiurolithic, Urolithiasis
